Procedure guidelines for whole-body18F-FDG PET and PET/CT in children with malignant diseases;Empfehlungen zur Durchführung der Ganzkörper-18F-FDG- PET und -PET/CT bei Kindern mit onkologischen Erkrankungen: Anpassung der EANM-Guideline* an aktuelle Gegebenheiten in Deutschland

NuklearMedizin

Volumn 49, Issue 6, 2010, Pages 225-233

  Franzius, C ^a,h   Stauss, J ^b   Pfluger, T ^c   Juergens, K U ^a,h   Kluge, R ^d   Amthauer, H ^e   Juergens, H ^a   Henze, G ^f   Stoever, B ^g   Hahn, K ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^f HUMBOLDT UNIVERSITY   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h MR und PET/CT Zentrum Bremen Mitte   (Germany)

Author keywords

Children; FDG; Paediatrics; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GERMANY; HUMAN; MEDICAL SOCIETY; NUCLEAR MEDICINE; PEDIATRICS; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY SCANNER; PRACTICE GUIDELINE; PUBLICATION; RADIATION EXPOSURE; ULTRASOUND SCANNER;

BODY WEIGHT; CHILD; FLUORODEOXYGLUCOSE F18; GERMANY; HUMANS; NEOPLASMS; PEDIATRICS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78650764188     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0322     Document Type: Article

References (60)

1. Amthauer H, Furth C, Denecke T et al. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up. Klin Paediatr 2005; 217: 327-333. (Pubitemid 41746114)
2. Barrington S, Begent J, Lynch T et al. Guideline for the use of PET-CT in children. Nucl Med Commun 2008; 29: 418-424.
3. Bartenstein P, Asenbaum S, Catafau A et al. European Association of Nuclear Medicine procedure guidelines for brain imaging using F-18-FDG. Eur J Nucl Med Mol Imaging 2002; 29: BP43-48. (Pubitemid 44392230)
4. Bombardieri E, Aktolun C, Baum R et al. FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: BP115-124. (Pubitemid 38017441)
5. Brink I, Renhardt M, Hoegerle S et al. Increased metabolic activity in the thymus gland studied with F-18-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001; 42: 591-595. (Pubitemid 32298279)
6. Bundesamt für Strahlenschutz. Bekanntmachung der diagnostischen Referenzwerte für radiologische und nuklearmedizinische Untersuchungen. BAnz Nr. 143 vom 05.08.2003
7. Chugani H. A critical period of brain developement: studies of cerebral glucose utilization with PET. Prev Med 1998; 27: 184-188. (Pubitemid 28360839)
8. El Fakhri G, Holdsworth C, Badawi R et al. Impact of acquisition geometry and patient habitus on lesion detectability in whole body FDG-PET: a channelized hotelling observer study. IEEE Nuclear Science Symposium Conference Record, NJ: IEEE 2002; 3: 1402-1405.
9. Fahey F. Dosimetry of pediatric PET/CT. J Nucl Med 2009; 50: 1483-1491.
10. Fahey F, Palmer M, Strauss K et al. Dosimetry and adequacy of CT-based attenuation correction for pediatric PET: phantom study. Radiology 2007; 243: 96-104. (Pubitemid 46579699)
11. Franzius C, Daldrup-Link HE, Sciuk J et al. FDGPET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12: 479-486. (Pubitemid 32472101)
12. Franzius C, Daldrup-Link HE, Wagner-Bohn A et al. FDG PET for detection of recurrences from malignant primary bone tumors: Comparison with conventional imaging. Ann Oncol 2002; 13: 157-160. (Pubitemid 34436740)
13. Franzius C, Hartmann L, Juergens K et al. Analyse der PET-CT-Akquisitionsprotokolle pädiatrischer Patienten: Bildqualität, Kontrastierung, Strahlenexposistion. Nuklearmedizin 2008; 47: A79.
14. Franzius C, Hermann K, Weckesser M et al. Wholebody PET/CT with C-11-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with I-123-mIBG SPECT/CT. J Nucl Med 2006; 47: 1635-1642. (Pubitemid 47545029)
15. Franzius C, Juergens K, Schober O. Is PET/CT necessary in paediatric oncology? For. Eur J Nucl Med Mol Imaging 2006; 33: 960-965.
16. Franzius C, Juergens KU, Vormoor J. PET/CT with diagnostic CT in the evaluation of childhood sarcoma. Am J Roentgenol 2006; 186: 581. (Pubitemid 46100340)
17. Franzius C, Jrgens K. PET/CT in paediatric oncology: indications and pitfalls. Pediatr Radiol 2009; 39, Suppl 3: 446-449.
18. Franzius C, Schober O. Assessment of therapy response by FDG PET in Pediatric Patients. Q J Nucl Med 2003; 47: 41-45. (Pubitemid 36826760)
19. Franzius C, Sciuk J, Brinkschmidt C et al. Evaluation of chemotherapy response in primary bone tumors with F-18-FDG-PET compared with histologically assessed tumor necrosis. Clin Nucl Med 2000; 25: 874-881.
20. Franzius C, Sciuk J, Daldrup-Link HE et al. FDGPET for detection of osseous metastases from malignant primary bone tumors: comparison with bone scintigraphy. Eur J Nucl Med 2000; 27: 1305-1311.
21. Gelfand M. Dosimetry of FDG PET/CT and other molecular imaging applications in pediatric patients. Pediatr Radiol 2009; 39 (Suppl 1): S46-S56.
22. Gelfand M, O'Hara S, Curtwright L et al. Pre-medication to block F-18-FDG uptake in brown adipose tissue of pediatric and adolescent patients. Pediatr Radiol 2005; 35: 984-990. (Pubitemid 41403488)
23. Gerth H, Juergens K, Dirksen U et al. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing sarcoma. J Nucl Med 2007; 48: 1932-1939. (Pubitemid 350237602)
24. Gutzeit A, Debatin J, Antoch G. Tumor staging with PET/CT. Detection of a second tumor. Röfo 2004; 176: 122-124.
25. Hahn K, Fischer S. Radiation dose and radiation protection from paediatric nuclear medicine procedures. Der Nuklearmediziner 2002; 25: 90-100.
26. Hahn K, Pfluger T. Has PET become an important clinical tool in paediatric imaging. Eur J Nucl Med Mol Imaging 2004; 31: 615-621. (Pubitemid 38647898)
27. Hahn K, Pfluger T. Is PET/CT necassary in paediatric oncology? Against. Eur J Nucl Med Mol Imaging 2006; 33: 966-968.
28. Hawkins DS, Rajendran JG, Conrad EU et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-Fluorodeoxy-D-Glucose Positron Emission Tomography. Cancer 2002; 94: 3277-3284.
29. Hermann S, Wormanns D, Pixberg M et al. Staging in childhood lymphoma: differences between FDGPET and CT. Nuklearmedizin 2005; 44: 1-7. (Pubitemid 40314093)
30. Holm S, Borgwardt L, Loft A et al. Paediatric doses - a critical appraisal of the EANM paediatric dosage card. Eur J Nucl Med Mol Imaging 2007; 34: 1713-1718. (Pubitemid 47599062)
31. Hudson MM, Krasin MJ, Kaste SC. PET imaging in pediatric Hodgkin's lymphoma. Pediatr Radiol 2004; 34: 190-198. (Pubitemid 38396972)
32. ICRP. Publication 80: Radiation dose to patients from radiopharmaceuticals. Vol. 28, 3. Oxford: Pergamon Press, 1998.
33. Jacobs F, Thierens H, Piepsz A et al. Optimized tracer-dependent dosage cards to obtain weight-independent effective doses. Eur J Nucl Med Mol Imaging 2005; 32: 581-588. (Pubitemid 41217418)
34. Jadvar H, Connolly L, Fahey F et al. PET and PET/ CT in pediatric oncology. Semin Nucl Med 2007; 37: 316-331.
35. Jürgens K, Weckesser M, Stegger L et al. Tumor staging using whole-body high-resolution 16-channel PET-CT: Does additional low-dose chest CT in inspiration improve the detection of solitary pulmonary nodules? Eur Radiol 2006; 16: 1131-1137.
36. Kaste S. F-18-PET-CT in extracranial paediatric oncology: when and for whom is it useful. Pediatr Radiol 2008; 38: S459-S466. (Pubitemid 351678160)
37. Kaste S. Issues specific to implementing PET-CT for pediatric oncology: what have we learned along the way. Pediatr Radiol 2004; 34: 205-213. (Pubitemid 38396974)
38. Kaste SC, Howard SC, McCarville EB et al. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol 2005; 35: 141-154.
39. Kobe C, Dietlein M, Mauz-Krholz C et al. FDGPET beim Hodgkin-Lymphom. Nuklearmedizin 2008; 47: 225-274.
40. Körholz D, Kluge R, Wickmann L et al. Importance of F-18-fluorodeoxy-D-2-glucose positron emission tomographie (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol. Onkologie 2003; 26: 489-493.
41. Kotzerke J, Oehme L, Lindner O et al. Positron emission tomography 2008, Results of the query and current status. Nuklearmedizin 2010; 49: 58-64.
42. Krause B, Beyer T, Bockisch A et al. FDG-PET/CT in der Onkologie. Nuklearmedizin 2007; 46: 291-301.
43. Kushner BH, Yeung HW, Larson SM et al. Extending positron emission tomography scan utility to highrisk neuroblastoma: fluorine-18- fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19: 3397-3405.
44. la Fougère C, Pfluger T, Schneider V et al. Restaging von Lymphom-Patienten mit PET/CT - Vergleich von Niedrigdosis-CT (20 mAs) mit kontrastmittelverstärkter diagnostischer CT. Nuklearmedizin 2009; 47: 37-42.
45. Lassmann M, Biassoni L, Monieurs M et al. The new EANM dosage card. Eur J Nucl Med Mol Imaging 2007; 34: 796-798.
46. Lassmann M, Biassoni L, Monsieurs M et al. The new EANM paediatric dosage card. Additional notes with respect to F-18. Eur J Nucl Med Mol Imaging 2008; 35: 1748.
47. Lucas JD, O'Doherty MJ, Cronin BF et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999; 86: 550-556. (Pubitemid 29195057)
48. Lucas JD, O'Doherty MJ, Wong JCH et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcoma. J Bone Joint Surg (Br) 1998; 80-B: 441-447. (Pubitemid 28230573)
49. McCarville MB, Christie R, Daw NC et al. PET/CT in evaluation of childhood sarcomas. Am J Roentgenol 2005; 184: 1293-1304.
50. Montravers F, McNamara D, Landman-Parker J et al. 18F-FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med 2002; 29: 1155-1165. (Pubitemid 34985360)
51. O'Hara SA, Donnelly LF, Coleman RE. Pediatric body applications of FDG PET. Am J Roentgen 1999; 172: 1019-1024. (Pubitemid 29505631)
52. Parysow O, Mollerach A, Jager V et al. Low-dose oral propanolol could reduce brow adipose tissue F-18 FDG uptake in patients undergoing PET scans. Clin Nucl Med 2007; 32: 351-357. (Pubitemid 46659166)
53. Shulkin B. PET applications in pediatrics. Q J Nucl Med 1997; 41: 281-291.
54. Shulkin BL, Hutchinson RJ, Castle VP et al. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996; 199: 743-750.
55. Söderlund V, Larsson S, Jacobsson H. Reduction of FDG uptake in brow adipose tissue in clinical patients by a single dose of propanolol. Eur J Nucl Med Mol Imaging 2007; 34: 1018-1022. (Pubitemid 46919548)
56. Stabin M, Gelfand M. Dosimetry of pediatric nuclear medicine procedures. Q J Nucl Med 1998; 42: 93-112. (Pubitemid 28343355)
57. Stauss J, Franzius C, Pfluger T et al. Guideline for F-18-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging 2008; 35: 1581-1588.
58. Voelker T, Denecke T, Steffen I et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25: 5435-5441. (Pubitemid 350232220)
59. Warbey V, Schleyer P, Barrington S et al. The new EANM paediatric dosage card - does it conform to ALARA for PET/CT. Eur J Nucl Med Mol Imaging 2007; 34: 1881-1882. (Pubitemid 47599067)
60. Wegner E, Barrington S, Kingston J et al. The impact of PET scanning on management of paediatric oncology patients. Eur J Nucl Med Mol Imaging 2005; 32: 23-30. (Pubitemid 40142775)